Halozyme Therapeutics, Inc. (HALO)
68.44
+0.08
(+0.12%)
USD |
NASDAQ |
Dec 24, 12:59
68.00
-0.44
(-0.64%)
After-Hours: 13:59
Halozyme Therapeutics SG&A Expense (TTM): 172.31M for Sept. 30, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Johnson & Johnson | 23.38B |
| Merck & Co., Inc. | 10.70B |
| ANI Pharmaceuticals, Inc. | 304.67M |
| Bristol Myers Squibb Co. | 7.222B |
| AIM ImmunoTech, Inc. | 10.06M |